hVIVO primed for profitability next year

The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June 30


hVIVO PLC (LON:HVO) said it is primed for profitability next year.

The projection was made alongside interim results, which revealed £11mln of costs have been extracted from clinical development services business since 2017.

The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June 30, up £1mln year-on-year, or 20%.

The adjusted operating loss narrowed by more than a quarter to £3.7mln, while research and development spend fell by 60% to just £1.1mln.

More importantly, hVIVO had cash and equivalents of £4mln at the period-end, supplement by an R&D credit worth £2.4mln that was paid earlier this month.

"In the first half of 2019 we have continued to rationalise the company's cost base to further reduce our operating costs and improved our operating efficiency,” said chairman Trevor Phillips.

Operationally, the focus has been on the efficiencies that will get the business beyond break-even, hVIVO said.

It did reveal there had been an “unprecedented levels of contract cancellations”, due to client portfolio prioritisation, that had hit the cash position at “a time when business turnaround and efficiencies are still to be fully realised”.

Looking ahead, the 2020 pipeline is looking “strong”, hVIVO added. Nearer-term, it has entered the second half with a “robust backlog of contracted work”, despite the aforementioned cancellations.

"We have made progress in expanding our service offerings to enhance revenue opportunities, delivered further successful client studies and extend our position as a leader in viral challenge studies,”  chairman Phillips added.

Quick facts: hVIVO PLC

Price: - -

Market: LSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...



hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

on 10/12/19

2 min read